7UKS

Crystal structure of SOS1 with phthalazine inhibitor bound (compound 15)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.29 Å
  • R-Value Free: 0.275 
  • R-Value Work: 0.242 
  • R-Value Observed: 0.244 

Starting Model: experimental
View more details

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history


Literature

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.

Ketcham, J.M.Haling, J.Khare, S.Bowcut, V.Briere, D.M.Burns, A.C.Gunn, R.J.Ivetac, A.Kuehler, J.Kulyk, S.Laguer, J.Lawson, J.D.Moya, K.Nguyen, N.Rahbaek, L.Saechao, B.Smith, C.R.Sudhakar, N.Thomas, N.C.Vegar, L.Vanderpool, D.Wang, X.Yan, L.Olson, P.Christensen, J.G.Marx, M.A.

(2022) J Med Chem 65: 9678-9690

  • DOI: https://doi.org/10.1021/acs.jmedchem.2c00741
  • Primary Citation of Related Structures:  
    7UKR, 7UKS

  • PubMed Abstract: 

    SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS G12C protein-protein interaction (PPI) can increase the proportion of GDP-loaded KRAS G12C , providing a strong mechanistic rationale for combining inhibitors of the SOS1:KRAS complex with inhibitors like MRTX849 that target GDP-loaded KRAS G12C . In this report, we detail the design and discovery of MRTX0902─a potent, selective, brain-penetrant, and orally bioavailable SOS1 binder that disrupts the SOS1:KRAS G12C PPI. Oral administration of MRTX0902 in combination with MRTX849 results in a significant increase in antitumor activity relative to that of either single agent, including tumor regressions in a subset of animals in the MIA PaCa-2 tumor mouse xenograft model.


  • Organizational Affiliation

    Mirati Therapeutics, 3545 Cray Court, San Diego, California 92121, United States.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Son of sevenless homolog 1487Homo sapiensMutation(s): 0 
Gene Names: SOS1
UniProt & NIH Common Fund Data Resources
Find proteins for Q07889 (Homo sapiens)
Explore Q07889 
Go to UniProtKB:  Q07889
PHAROS:  Q07889
GTEx:  ENSG00000115904 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ07889
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
NL0 (Subject of Investigation/LOI)
Query on NL0

Download Ideal Coordinates CCD File 
B [auth A]4-methyl-N-{(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl}-7-(piperazin-1-yl)phthalazin-1-amine
C23 H26 F3 N5
MJSKXOIIHARCLW-OAHLLOKOSA-N
Binding Affinity Annotations 
IDSourceBinding Affinity
NL0 BindingDB:  7UKS Ki: min: 0.11, max: 0.33 (nM) from 2 assay(s)
IC50: 47 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.29 Å
  • R-Value Free: 0.275 
  • R-Value Work: 0.242 
  • R-Value Observed: 0.244 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 40.792α = 90
b = 89.102β = 90
c = 172.316γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
HKL-2000data reduction
HKL-2000data scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2022-07-27
    Type: Initial release
  • Version 1.1: 2022-08-03
    Changes: Structure summary
  • Version 1.2: 2022-08-10
    Changes: Database references
  • Version 1.3: 2023-10-18
    Changes: Data collection, Refinement description